Teleflex Incorporated (NYSE:TFX) Given Consensus Recommendation of “Reduce” by Brokerages

Shares of Teleflex Incorporated (NYSE:TFX) have received an average recommendation of “Reduce” from the twelve analysts that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, nine have issued a hold recommendation and one has given a buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $142.4286.

A number of equities research analysts have recently commented on TFX shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Teleflex in a research report on Monday, December 29th. Truist Financial raised their price target on Teleflex from $120.00 to $135.00 and gave the stock a “hold” rating in a research note on Thursday, December 18th. Needham & Company LLC restated a “hold” rating on shares of Teleflex in a report on Tuesday, December 9th. Zacks Research lowered shares of Teleflex from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 30th. Finally, Wall Street Zen cut shares of Teleflex from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th.

Teleflex Stock Performance

Shares of TFX opened at $122.49 on Friday. Teleflex has a 1 year low of $102.58 and a 1 year high of $185.94. The company’s 50 day simple moving average is $119.09 and its 200 day simple moving average is $121.07. The company has a market capitalization of $5.41 billion, a price-to-earnings ratio of -16.67, a PEG ratio of 1.36 and a beta of 0.93. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.53 and a current ratio of 2.57.

Teleflex (NYSE:TFX) last released its earnings results on Thursday, November 6th. The medical technology company reported $3.67 EPS for the quarter, topping the consensus estimate of $3.38 by $0.29. The firm had revenue of $892.90 million during the quarter, compared to analysts’ expectations of $892.79 million. Teleflex had a negative net margin of 10.28% and a positive return on equity of 15.64%. Teleflex’s revenue for the quarter was up 19.4% on a year-over-year basis. During the same period in the previous year, the company earned $3.49 EPS. Teleflex has set its FY 2025 guidance at 14.000-14.200 EPS. On average, sell-side analysts predict that Teleflex will post 13.98 EPS for the current year.

Teleflex Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, December 15th. Shareholders of record on Friday, November 14th were issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date was Friday, November 14th. Teleflex’s dividend payout ratio (DPR) is -18.50%.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. JPMorgan Chase & Co. grew its position in Teleflex by 41.5% during the third quarter. JPMorgan Chase & Co. now owns 123,343 shares of the medical technology company’s stock valued at $15,092,000 after acquiring an additional 36,178 shares during the period. Allworth Financial LP lifted its stake in shares of Teleflex by 451.9% in the 3rd quarter. Allworth Financial LP now owns 1,490 shares of the medical technology company’s stock valued at $182,000 after purchasing an additional 1,220 shares in the last quarter. Swiss Life Asset Management Ltd purchased a new stake in shares of Teleflex during the 3rd quarter worth about $250,000. Caerus Investment Advisors LLC acquired a new stake in Teleflex during the 3rd quarter worth approximately $477,000. Finally, Captrust Financial Advisors increased its position in Teleflex by 287.0% during the 3rd quarter. Captrust Financial Advisors now owns 17,179 shares of the medical technology company’s stock worth $2,102,000 after purchasing an additional 12,740 shares in the last quarter. 95.62% of the stock is owned by hedge funds and other institutional investors.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.